- $12.45m
- -$302.20m
- $213.65m
Ireland's Amarin Q2 revenue falls on lower licensing payments
Amarin Corporation PLC expected to post a loss of 1 cent a share - Earnings Preview
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)
US Supreme Court backs generic drugmaker in 'skinny label' patent case
US appeals court revives Amarin heart-drug patent lawsuit over Hikma generic - June 25, 2024
US Supreme Court hears patent case with potentially sweeping implications for generics
Ireland's Amarin Q1 revenue rises 7% on higher international sales
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Amarin rises as heart drug spotlighted at major cardiology meet
Amarin Q4 revenue falls 21% on lower sales outside US, Europe
US Supreme Court to hear 'skinny label' patent fight involving Amarin (updated)
US Supreme Court to hear 'skinny label' patent fight involving Amarin
Amarin Q3 revenue up 17%, operating loss narrows
Brief: Amarin Issues Statement Supporting FDA’S Action To Revise Labeling For Fenofibrate Drugs Reinforcing A Lack Of Cardiovascular Benefit
Amarin Corporation PLC reports results for the quarter ended June 30 - Earnings Summary
Brief: Amarin Reports Second Quarter 2025 Financial Results
Amarin Corporation PLC expected to post a loss of 18 cents a share - Earnings Preview